Literature DB >> 18622416

Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation.

F Schlemmer, M Lagrange-Xélot, C Lacroix, R de La Tour, G Socié, J-M Molina.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18622416     DOI： 10.1038/bmt.2008.199

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  9 in total

1.  Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.

Authors:  Teclegiorgis Gebremariam; Sondus Alkhazraji; Clara Baldin; Laura Kovanda; Nathan P Wiederhold; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.

Authors:  Gloria Mattiuzzi; Musa Yilmaz; Hagop Kantarjian; Gautam Borthakur; Marina Konopleva; Elias Jabbour; Yolanda Brown; Sherry Pierce; Jorge Cortes
Journal:  J Infect Chemother       Date:  2015-06-09       Impact factor: 2.211

3.  Prophylactic Treatment with VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection.

Authors:  Teclegiorgis Gebremariam; Sondus Alkhazraji; Lin Lin; Nathan P Wiederhold; Edward P Garvey; William J Hoekstra; Robert J Schotzinger; Thomas F Patterson; Scott G Filler; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

4.  Recent advances in the treatment of mucormycosis.

Authors:  Brad Spellberg; Ashraf S Ibrahim
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

Review 5.  Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).

Authors:  Anna Skiada; Fanny Lanternier; Andreas H Groll; Livio Pagano; Stephan Zimmerli; Raoul Herbrecht; Olivier Lortholary; George L Petrikkos
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

6.  Risk-based antifungal prophylaxis in hematologic malignancy and stem cell transplantation.

Authors:  Joshua Wolf; Monica A Slavin
Journal:  Curr Infect Dis Rep       Date:  2009-11       Impact factor: 3.725

Review 7.  Foiling fungal disease post hematopoietic cell transplant: review of prophylactic strategies.

Authors:  S M Rubinstein; K A Culos; B Savani; G Satyanarayana
Journal:  Bone Marrow Transplant       Date:  2017-10-23       Impact factor: 5.483

8.  Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis.

Authors:  Seung Hun Kang; Hyun Seon Kim; Myoung Nam Bae; Jihye Kim; Ji Yeon Yoo; Kwan Yong Lee; Dong-Gun Lee; Hee-Je Kim
Journal:  Infect Chemother       Date:  2015-03-30

9.  In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer Triazoles.

Authors:  Andrew M Borman; Mark Fraser; Zoe Patterson; Michael D Palmer; Elizabeth M Johnson
Journal:  J Fungi (Basel)       Date:  2021-04-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.